Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis

Kovalik, Marcel; Mellanby, Richard J.; Evans, Helen; Berry, Jacqueline; Broek, Adri H. M. van den; Thoday, Keith L.

doi:10.1111/j.1365-3164.2012.01119.x

Cited by 5 publications

(4 citation statements)

References 53 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a higher serum iPTH level was found in CsA users who also received low-dose GC. These results were consistent with those reported by Kovalik et al [38], who showed a significantly increased serum iPTH level in atopic dogs undergoing CsA therapy. Despite this consistency, we have found an inverse correlation between serum iPTH and the cumulative dose of GC (r=−0.299, p=0.011), suggesting that GC and CsA are reciprocally antagonizing each other in their interaction with iPTH.…”

Section: Fgf-23 Bone Metabolism and Fgf-23 Determinantssupporting

confidence: 83%

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Fgf-23 Bone Metabolism and Fgf-23 Determinantssupporting

confidence: 83%

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Despite this, there are no published descriptions of altered bone density or an increased risk of fractures in atopic dogs. In one study, 16 atopic dogs treated with 4.4‐6.0 mg/kg ciclosporin every 24 hours for six weeks showed no significant changes in serum concentrations of plasma total and ionised calcium, phosphate, creatinine, 25(OH)D, 1,25(OH)2D, or urinary fractional excretion of calcium and phosphate (Kovalik and others 2012). Mean plasma PTH concentrations significantly increased following ciclosporin treatment, but the proportion of dogs with plasma PTH levels above the reference range was similar before and after treatment.…”

Section: Effects On Systemic Metabolism and Homeostasismentioning

confidence: 99%

Life‐long diseases need life‐long treatment: long‐term safety of ciclosporin in canine atopic dermatitis

2014

View full text Add to dashboard Cite

Ciclosporin (Atopica; Novartis Animal Health) has been licensed for canine atopic dermatitis (AD) since 2002. Adverse events (AEs) have been reported in 55 per cent of 759 dogs in 15 clinical trials, but are rare in pharmacovigilance data (71.81 AEs/million capsules sold). Gastrointestinal reactions were most common, but were mild and rarely required intervention. Other AEs were rare (≤1 per cent in clinical trials; <10/million capsules sold). Hirsutism, gingival hyperplasia and hyperplastic dermatitis were rarely significant and resolved on dose reduction. Ciclosporin decreases staphylococcal and Malassezia infections in AD, and at the recommended dose is not a risk factor for other infections, neoplasia, renal failure or hypertension. The impact on glucose and calcium metabolism is not clinically significant for normal dogs. Concomitant treatment with most drugs is safe. Effects on cytochrome P450 and MDR1 P-glycoprotein activity may elevate plasma ciclosporin concentrations, but short-term changes are not clinically significant. Monitoring of complete blood counts, urinalysis or ciclosporin levels is not justified except with higher than recommended doses and/or long-term concurrent immunosuppressive drugs. Ciclosporin is not a contraindication for killed (including rabies) vaccines, but the licensed recommendation is that live vaccination is avoided during treatment. In conclusion, ciclosporin has a positive risk-benefit profile for the long-term management of canine AD.

show abstract

“…One of the most popular thus far has been an intact immunoradiometric assay (IRMA) (Allegro Intact PTH; Nichols Institute Diagnostics) fully validated for use in dogs (Torrance & Nachreiner ,). However, this assay, other similar intact PTH IRMAs and non‐isotopic assays (Intact PTH; Diagnostic Products Corporation; Intact PTH; Diagnostic Systems Laboratory and Liaison iPTH; DiaSorin) previously used in dogs (Gow et al , , Kovalik et al ,, Selting et al , Young & Backus ) are no longer available.…”

Section: Introductionmentioning

confidence: 99%

A comparison of canine whole and intact parathyroid hormone concentrations as measured by different assays

Mooney

Shiel

Fawcett

et al. 2019

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To compare an intact immunoradiometric parathyroid hormone assay with (1) a non‐isotopic technique; and, (2) a whole parathyroid hormone immunoradiometric assay. Materials and Methods Intact parathyroid hormone concentrations were measured using immunoradiometric (Scantibodies) and chemiluminescent (Immulite 2000) assays. Whole parathyroid hormone concentration was measured using an immunoradiometric assay (Scantibodies). Results A total of 48 and 47 samples, respectively, were used to compare immunoradiometric and chemiluminescent intact parathyroid concentrations and intact and whole parathyroid hormone concentrations by immunoradiometric assays. Using chemiluminescence, 39 (81.3%) samples had intact parathyroid hormone concentrations at or below the reported limit of detection of the assay (0.3 pmol/L). Intact [6.3 (2.0 to 95.5) pmol/L] and whole [3.3 (0.8 to 125.2) pmol/L] immunoradiometric parathyroid hormone concentrations exhibited excellent correlation. Clinical Significance Not all parathyroid hormone assays perform similarly. The chemiluminescent assay in this study cannot be recommended for use in dogs. The immunoradiometric intact parathyroid hormone assay proved to be a more reliable method. Given the correlation between intact and whole parathyroid hormone concentrations, it remains unclear which one is superior for routine clinical decision‐making.

show abstract

Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis

Abstract: This study indicates that ciclosporin has minimal impact on calcium metabolism in dogs with atopic dermatitis when used at the licensed and clinically effective dosage for 6 weeks.

Cited by 5 publications

References 53 publications

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

Life‐long diseases need life‐long treatment: long‐term safety of ciclosporin in canine atopic dermatitis

A comparison of canine whole and intact parathyroid hormone concentrations as measured by different assays

Contact Info

Product

Resources

About